Liu Zhike, Meng Ruogu, Yang Yu, Li Keli, Yin Zundong, Ren Jingtian, Shen Chuanyong, Feng Zijian, Zhan Siyan
Department of Epidemiology and Biostatistics, Peking University Health Science Center, Beijing, China.
National Institute of Health Data Science, Peking University, Beijing, China.
Health Data Sci. 2021 Jun 12;2021:9851067. doi: 10.34133/2021/9851067. eCollection 2021.
. The great success in vaccine-preventable diseases has been accompanied by vaccine safety concerns. This has caused vaccine hesitancy to be the top 10 in threats to global health. The comprehensive understanding of adverse events following immunization should be entirely based on clinical trials and postapproval surveillance. It has increasingly been recognized worldwide that the active surveillance of vaccine safety should be an essential part of immunization programs due to its complementary advantages to passive surveillance and clinical trials.. In the present study, the framework of vaccine safety surveillance was summarized to illustrate the importance of active surveillance and address vaccine hesitancy or safety concerns. Then, the global progress of active surveillance systems was reviewed, mainly focusing on population-based or hospital-based active surveillance. With these successful paradigms, the practical and reliable ways to create robust and similar systems in China were discussed and presented from the perspective of available databases, methodology challenges, policy supports, and ethical considerations.. In the inevitable trend of the global vaccine safety ecosystem, the establishment of an active surveillance system for vaccine safety in China is urgent and feasible. This process can be accelerated with the consensus and cooperation of regulatory departments, research institutions, and data owners.
疫苗可预防疾病方面的巨大成功伴随着对疫苗安全性的担忧。这使得疫苗犹豫成为全球健康面临的十大威胁之一。对免疫接种后不良事件的全面理解应完全基于临床试验和批准后监测。全世界越来越认识到,疫苗安全性的主动监测因其对被动监测和临床试验的互补优势,应成为免疫规划的重要组成部分。在本研究中,总结了疫苗安全性监测框架,以说明主动监测的重要性并解决疫苗犹豫或安全性担忧问题。然后,回顾了主动监测系统的全球进展,主要侧重于基于人群或基于医院的主动监测。借助这些成功范例,从可用数据库、方法学挑战、政策支持和伦理考量等角度,讨论并提出了在中国创建强大且类似系统的切实可行方法。在全球疫苗安全生态系统的必然趋势下,在中国建立疫苗安全性主动监测系统既紧迫又可行。监管部门、研究机构和数据所有者达成共识并开展合作,这一进程便可加速。